NEW YORK (GenomeWeb News) – The Translational Genomics Research Institute’s TGen Drug Development (TD2) arm will use Horizon Discovery’s isogenic cell lines in a partnership focused on developing pharmacogenomic tools for use in cancer drug research services, TGen said today.
The partners will use Horizon Discovery Services’ panel of more than 200 genetically-defined X-Man human isogenic cell lines in TD2’s comprehensive pre-clinical service before it conducts certain in-house clinical trials.
TD2 will provide high-throughput screening capabilities, study execution, and business marketing for the service offerings, and it may offer new services that emerge from TGen and the Van Andel Institute, an affiliate of TGen.
Horizon will support the preclinical offerings with tailored 2D and 3D assay formats that mimic the in vivo phenotype being driven by primary and secondary cancer mutations.
“The future of oncology drug development will require us to predict which patients will respond to what drug, TD2 President and CSO Stephen Gately said in a statement. “This partnership is the engine that will actually make this work and allow for the design of shorter and less-costly clinical trials that enroll the patients most likely to respond to a given drug."
This agreement builds on another from earlier this year between Horizon and TGen to develop new human disease models for TGen’s cancer research programs.